Company profile: Genoplan
1.1 - Company Overview
Company description
- Provider of DNA testing and genetic analysis services, offering health risk prediction to support informed decisions, pregnancy genetic testing to identify genetic disorder risks for family planning, and traits & ancestry insights into characteristics and lineage.
Products and services
- Pregnancy: DNA-based genetic testing service that identifies risks of genetic disorders for family planning, guiding reproductive decisions with inherited risk insights
- Healthier life: Genetic-analysis-driven service predicting the likelihood of developing diseases, enabling individuals to make informed health decisions through personalized disease risk estimation
- Traits & Ancestry: DNA-testing-enabled service offering insights into an individual's ancestry and genetic tendencies towards various characteristics, clarifying heritage and trait predispositions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Genoplan
NAT Diagnostics
HQ: United States
Website
- Description: Provider of a molecular diagnostic platform for true point-of-care infectious disease testing in physician offices, clinics, pharmacies, and other sites where patients are seen by medical personnel, delivering highly accurate results to improve the diagnostic experience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NAT Diagnostics company profile →
Pivot Bio
HQ: United States
Website
- Description: Provider of microbial nitrogen solutions for crop nutrition, including Pivot Bio PROVEN® 40 for corn and RETURN® for wheat and small grains, delivering steady nitrogen at the root on-seed or in-furrow; the N-OVATOR™ program that rewards reduced synthetic fertilizer use; and NLIGHTEN®, an in-furrow tank system for precise microbial nitrogen delivery with equipment reimbursement.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pivot Bio company profile →
MS-Omics
HQ: Denmark
Website
- Description: Provider of metabolomics and data analysis services for small to large studies, offering fee-for-service analyses to universities and companies in biotechnology, pharmacy, and food. Capabilities include microbiome metabolite measurement (with Clinical-Microbiomics for next-generation sequencing), clinical, cell and bacteria, nutritional, and animal metabolomics, leveraging advanced mass spectrometry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MS-Omics company profile →
Nutcracker Therapeutics
HQ: United States
Website
- Description: Provider of mRNA therapeutics and an integrated RNA manufacturing platform: the Nutcracker Manufacturing Unit (NMU) for rapid mRNA production from DNA sequences; GMP-in-a-box to lower costs and cycle times; CodonCracker software to optimize RNA sequences; Nutshell delivery vehicles; an RNA therapeutics pipeline across HPV-driven tumors, T cell lymphoma, and genitourinary tumors; and strategic collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nutcracker Therapeutics company profile →
eGenesis
HQ: United States
Website
- Description: Provider of gene editing and genome engineering solutions to create human-compatible porcine organs and cells for transplantation. Offers HuCo organs and cells via the EGEN Platform, which addresses cross-species molecular incompatibilities and viral risks, enabling xenotransplantation to help address the global organ shortage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eGenesis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Genoplan
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Genoplan
2.2 - Growth funds investing in similar companies to Genoplan
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Genoplan
4.2 - Public trading comparable groups for Genoplan
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →